Celldex Therapeutics Inc. (NASDAQ:CLDX) shares dropped 1.1% on Friday . The company traded as low as $4.59 and last traded at $4.60, with a volume of 605,936 shares changing hands. The stock had previously closed at $4.65.

CLDX has been the topic of a number of recent research reports. Jefferies Group restated a “hold” rating and set a $4.00 price target on shares of Celldex Therapeutics in a report on Friday, May 6th. Roth Capital restated a “buy” rating and set a $7.00 price target on shares of Celldex Therapeutics in a report on Tuesday, April 19th. Cowen and Company restated an “outperform” rating and set a $12.00 price target on shares of Celldex Therapeutics in a report on Tuesday, June 7th. Finally, Wedbush restated a “neutral” rating and set a $3.00 price target on shares of Celldex Therapeutics in a report on Friday, May 6th. Six analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $14.11.

The company’s market cap is $458.05 million. The stock has a 50-day moving average of $4.42 and a 200-day moving average of $6.30.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting analysts’ consensus estimates of ($0.35). The business had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.06 million. During the same period in the prior year, the business posted ($0.33) earnings per share. Celldex Therapeutics’s revenue was up 160.0% compared to the same quarter last year. Analysts forecast that Celldex Therapeutics Inc. will post ($1.34) earnings per share for the current year.

A number of institutional investors have added to or reduced their stakes in the company. TSP Capital Management Group LLC raised its position in Celldex Therapeutics by 0.8% in the fourth quarter. TSP Capital Management Group LLC now owns 831,648 shares of the biopharmaceutical company’s stock worth $13,040,000 after buying an additional 6,967 shares in the last quarter. Bedell Frazier Investment Counseling LLC raised its position in Celldex Therapeutics by 9.0% in the fourth quarter. Bedell Frazier Investment Counseling LLC now owns 65,236 shares of the biopharmaceutical company’s stock worth $1,023,000 after buying an additional 5,411 shares in the last quarter. Columbia Wanger Asset Management LLC raised its position in Celldex Therapeutics by 16.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 3,610,008 shares of the biopharmaceutical company’s stock worth $56,605,000 after buying an additional 500,393 shares in the last quarter. ProShare Advisors LLC raised its position in Celldex Therapeutics by 10.7% in the fourth quarter. ProShare Advisors LLC now owns 93,666 shares of the biopharmaceutical company’s stock worth $1,469,000 after buying an additional 9,072 shares in the last quarter. Finally, Columbus Circle Investors raised its position in Celldex Therapeutics by 10.5% in the fourth quarter. Columbus Circle Investors now owns 655,739 shares of the biopharmaceutical company’s stock worth $10,282,000 after buying an additional 62,246 shares in the last quarter.

Celldex Therapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.